Jens Voortman

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

Implementation of a Self-Help Swallowing Exercise Program in Head and Neck Cancer.

Implementation of a Self-Help Swallowing Exercise Program in Head and Neck Cancer.

Journal: Folia phoniatrica et logopaedica : official organ of the International Association of Logopedics and Phoniatrics (IALP)

Published: March 10, 2026

Longitudinal genome-wide aneuploidy measurements in circulating cell-free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer.

Longitudinal genome-wide aneuploidy measurements in circulating cell-free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer.

Journal: Molecular oncology

Published: November 10, 2025

How Does Routine Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Modify the Current Management of Prostate Cancer? A Multidisciplinary View.

How Does Routine Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Modify the Current Management of Prostate Cancer? A Multidisciplinary View.

Journal: European urology open science

Published: March 16, 2025

Novel Molecular Biomarkers to Guide Treatment Decision-making in Metastatic Urothelial Cancer-A Patient Cohort Analysis.

Novel Molecular Biomarkers to Guide Treatment Decision-making in Metastatic Urothelial Cancer-A Patient Cohort Analysis.

Journal: European urology oncology

Published: December 19, 2024

Effect of hydration schedules on dose-limiting toxicity in patients with head and neck squamous cell carcinoma treated with cisplatin.

Effect of hydration schedules on dose-limiting toxicity in patients with head and neck squamous cell carcinoma treated with cisplatin.

Journal: British journal of clinical pharmacology

Published: October 25, 2024

Circulating T cell status and molecular imaging may predict clinical benefit of neoadjuvant PD-1 blockade in oral cancer.

Circulating T cell status and molecular imaging may predict clinical benefit of neoadjuvant PD-1 blockade in oral cancer.

Journal: Journal for immunotherapy of cancer

Published: June 30, 2024

The narrow road to expanded access.

The narrow road to expanded access.

Journal: Journal of cancer policy

Published: April 14, 2024

No prime time yet for checkpoint inhibitors in localised head and neck squamous cell carcinoma.

No prime time yet for checkpoint inhibitors in localised head and neck squamous cell carcinoma.

Journal: The Lancet. Oncology

Published: April 01, 2024

Low dose cisplatin weekly versus high dose cisplatin every three weeks in primary chemoradiotherapy in head and neck cancer patients with low skeletal muscle mass: The CISLOW-study protocol.

Low dose cisplatin weekly versus high dose cisplatin every three weeks in primary chemoradiotherapy in head and neck cancer patients with low skeletal muscle mass: The CISLOW-study protocol.

Journal: PloS one

Published: July 31, 2023

Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer.

Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer.

Journal: Nature communications

Published: June 17, 2022

Survival outcomes of patients with muscle-invasive bladder cancer according to pathological response at radical cystectomy with or without neo-adjuvant chemotherapy: a case-control matching study.

Survival outcomes of patients with muscle-invasive bladder cancer according to pathological response at radical cystectomy with or without neo-adjuvant chemotherapy: a case-control matching study.

Journal: International urology and nephrology

Published: June 03, 2022

Phase 1 Study of Chemoradiotherapy Combined with Nivolumab ± Ipilimumab for the Curative Treatment of Muscle-invasive Bladder Cancer.

Phase 1 Study of Chemoradiotherapy Combined with Nivolumab ± Ipilimumab for the Curative Treatment of Muscle-invasive Bladder Cancer.

Journal: European urology

Published: February 25, 2022

Showing 1-12 of 36

Last Updated: 09/26/2026